1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline Review, H2 2020, provides an overview of the Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) pipeline landscape.
Ebola is a rare but deadly viral infection that causes bleeding inside and outside the body. Signs and symptoms include fever, severe headache, joint and muscle aches, sore throat, nausea and vomiting, diarrhea, chest pain and cough. Supportive therapy includes oxygen therapy, blood transfusions, intravenous fluids and pain relievers.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Ebolavirus Infections (Ebola Hemorrhagic Fever) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 3, 2, 7, 59, 25 and 3 respectively. Similarly, the Universities portfolio in Phase III, Phase I, Preclinical and Discovery stages comprises 1, 4, 13 and 7 molecules, respectively.
Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
IntroductionEbolavirus Infections - Overview
Ebolavirus Infections - Therapeutics Development
Ebolavirus Infections - Therapeutics Assessment
Ebolavirus Infections - Companies Involved in Therapeutics Development
Ebolavirus Infections - Drug Profiles
Ebolavirus Infections - Dormant Projects
Ebolavirus Infections - Discontinued Products
Ebolavirus Infections - Product Development Milestones
Appendix
List of Tables
- Number of Products under Development for Ebolavirus Infections (Ebola Hemorrhagic Fever), H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Products under Development by Companies, H2 2020
- Products under Development by Universities/Institutes, H2 2020
- Number of Products by Stage and Target, H2 2020
- Number of Products by Stage and Mechanism of Action, H2 2020
- Number of Products by Stage and Route of Administration, H2 2020
- Number of Products by Stage and Molecule Type, H2 2020
- Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Abivax SA, H2 2020
- Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by AIkido Pharma Inc, H2 2020
- Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by AIM ImmunoTech Inc, H2 2020
- Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Akshaya Bio Inc, H2 2020
- Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by AnGes Inc, H2 2020
- Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by ANP Technologies Inc, H2 2020
- Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by AntoXa Corp, H2 2020
- Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Arisan Therapeutics Inc, H2 2020
- Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Atreca Inc, H2 2020
- Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Avipero Ltd, H2 2020
- Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Beijing Mabworks Biotech Co Ltd, H2 2020
- Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Bharat Biotech Ltd, H2 2020
- Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by BioComo Inc, H2 2020
- Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by BioCryst Pharmaceuticals Inc, H2 2020
- Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by BioFactura Inc, H2 2020
- Ebolavirus Infections (Ebola Hemorrhagic Fever) - Dormant Projects, H2 2020
- Ebolavirus Infections (Ebola Hemorrhagic Fever) - Discontinued Products, H2 2020
List of Figures
- Number of Products under Development for Ebolavirus Infections (Ebola Hemorrhagic Fever), H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Number of Products by Top 10 Targets, H2 2020
- Number of Products by Stage and Top 10 Targets, H2 2020
- Number of Products by Top 10 Mechanism of Actions, H2 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
- Number of Products by Top 10 Routes of Administration, H2 2020
- Number of Products by Stage and Top 10 Routes of Administration, H2 2020
- Number of Products by Top 10 Molecule Types, H2 2020
- Number of Products by Stage and Top 10 Molecule Types, H2 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abivax SA
- AIkido Pharma Inc
- AIM ImmunoTech Inc
- Akshaya Bio Inc
- AnGes Inc
- ANP Technologies Inc
- AntoXa Corp
- Arisan Therapeutics Inc
- Atreca Inc
- Avipero Ltd
- Beijing Mabworks Biotech Co Ltd
- Bharat Biotech Ltd
- BioComo Inc
- BioCryst Pharmaceuticals Inc
- BioFactura Inc
- Biotron Ltd
- Celdara Medical LLC
- Chicago Biosolutions Inc
- Cocrystal Pharma Inc
- Collaborations Pharmaceuticals Inc
- Eisai Co Ltd
- Emergent BioSolutions Inc
- Emergex Vaccines Ltd
- Etubics Corp
- Fab’entech SA
- Fibreu Ltd
- Flow Pharma Inc
- Fox Chase Chemical Diversity Center Inc
- Galactica Biotech Ltd
- Gamaleya Federal Research Center of Epidemiology and Microbiology
- GeoVax Labs Inc
- Gilead Sciences Inc
- Global BioLife Inc Ltd
- Greffex Inc
- H&P Labs Inc
- Humabs BioMed SA
- IDBiologics Inc
- Immunomodulation Inc
- Inovio Pharmaceuticals Inc
- Integral Molecular Inc
- Integrated BioTherapeutics Inc
- IntelliStem Technologies Inc
- Johnson & Johnson
- Mapp Biopharmaceutical Inc
- Merck & Co Inc
- Microbiotix Inc
- Micropharm Ltd
- Novavax Inc
- Oita University Institute of Advanced Medicine Inc
- OncXerna Therapeutics Inc
- Orgenesis Inc
- Ostrich Pharma USA Inc
- OyaGen Inc
- Palisades Therapeutics
- PanThera Biopharma LLC
- Phelix Therapeutics LLC
- Phoenix Biotechnology Inc
- Profectus BioSciences Inc
- Public Health Vaccines LLC
- Regeneron Pharmaceuticals Inc
- Riboscience LLC
- Ridgeback Biotherapeutics LP
- Rodos BioTarget GmbH
- SAB Biotherapeutics Inc
- Secarna Pharmaceuticals GmbH & Co. KG
- Selva Therapeutics Inc
- Soligenix Inc
- Tiba Biotech LLC
- Vaccibody AS
- Vaxeal Holding SA
- XBiotech Inc
- Xenothera SAS
- Yaso Therapeutics Inc
- Yisheng Biopharma Co Ltd
- Zalgen Labs LLC
